IVERMECTIN And FENBENDAZOLE Testimonials: Stage 2 Fallopian Tube Cancer, Stage 4 Breast Cancer With Lymph Node And Bone Metastases, 3 Months To Live Stomach Tumor
The first case involved the administration of the dubious and dangerous chemotherapy “treatment” combined with Ivermectin and Fenbendazole, and we can be all but certain that the only reason the patient is now in full remission is strictly due to the miraculous synergistic repurposed drugs:
IVERMECTIN And FENBENDAZOLE Testimonials: Stage 2 Fallopian Tube Cancer, Stage 4 Breast Cancer With Lymph Node And Bone Metastases, 3 Months To Live Stomach Tumor
In this Substack’s ongoing anecdotal repurposed drug crowdsourcing series comes another trio of absolutely incredible healing experiences courtesy of Dr. Makis.
The first case involved the administration of the dubious and dangerous chemotherapy “treatment” combined with Ivermectin and Fenbendazole, and we can be all but certain that the only reason the patient is now in full remission is strictly due to the miraculous synergistic repurposed drugs:
63 year old patient with a high grade serous Fallopian Tube Cancer asked me for help.
A few weeks later during HIPEC surgery, they couldn’t find any cancer cells.
Here is the patient’s recounting of the story:
“I saw the hematologist yesterday and he said no one at the tumor board could understand why the fluid showed no cancer.”
“He said in his whole career he has never seen anything like it. So rare to see such a thing. Then I told him that I went on Ivermectin and he laughed. He hopes@RobertKennedyJrcan get this legalized in the states and that I should share this news with the other doctors and surgeon that performed this surgery”“
He said his other patients are taking Ivermectin with chemo now.”
The doctor has never seen anything like it in his entire career, and yet he will still administer chemotherapy which he has seen his entire career kill off the majority of his patients.
This is the splitting of the difference of his career-long Medical Industrial Complex indoctrinated CogDis, and precisely why oncologists will increasingly add Ivermectin to their chemotherapy “treatments” because they can continue to extract astronomical profit margins from the latter, while actually now curing patients with the former; in other words, the Ivermectin will be used as both the cover and the cure for their deadly legacy allopathic treatments going forward.
The next case appears to have been an especially aggressive turbo cancer that required higher dosing protocols, but did not involve chemotherapy which further reinforces the aforementioned point that the Ivermectin and Fenbendazole are responsible for the remission, not the Medical Industrial Complex poisons; to wit:
STORY: 51 year old Canadian patient was diagnosed with Stage 4 Breast Cancer metastatic to lymph nodes and bones on Aug.2, 2024.
Makis Ivermectin Cancer Clinic Protocol was started in mid-August:
CT Scan: – Previous 5cm breast mass is smaller (hard to delineate from background) –
axillary lymph nodes slightly smaller
– lung nodules nearly completely resolved (!)
– bone metastases not commented on (bone scan showed decreased and more diffuse uptake consistent with treatment response)
My Take…
51 year old Stage 4 Breast Cancer patient had the following results after 5 months of Ivermectin Protocol (Ivermectin 96mg, Fenbendazole 888mg)
Conventional treatments: no chemo, 2 shots of Zoladex and 2x radiation to spine and femur. Patient refused Letrozole and Kisqali (ribociclib)
CA 15-3: 1386 to 94 (93% drop) (!!) CT Follow-up: Breast tumor, axillary nodes, lung nodules all shrinking and bone metastases healing
It wasn’t without a few challenges along the way
We’ve had to deal with a couple of asymptomatic episodes of elevated liver function tests. Patient is taking a lot of supplements.
But this has been a stunning response to treatment and an incredible success story!
Last but not least is yet another case of an oncologist making up an arbitrary death sentence timeframe for their patient, and ensuring that they die within said amount of time due to forcing upon them the torturously medieval chemotherapy “treatment:”
Never ever listen to any doctor pretending to know how long a patient will live, and always take your health into your own hands, or you will be another iatrogenic statistic.
And the following may very well represent the ultimate ‘holy grail’ cancer cure:
New & Improved Synergistic Joe Tippens Protocol
Tocotrienol and Tocopherol forms (all 8) of Vitamin E (400-800mg per day, 7 days a week). A product called Gamma E by Life Extension or Perfect E are both great.
Bio-Available Curcumin (600mg per day, 2 pills per day 7 days a week). A product called Theracurmin HP by Integrative Therapeutics is bioavailable.
Removing sugars and carbohydrates (cancer food) from your diet and replacing table sugar with a zero glycemic index, zero calorie, keto friendly rare sugar like FLAV-X
Anticancer Potential of Repurposed Drugs and Natural Compounds: A Focus on Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin
By Sid Belzberg
Introduction
In the evolving landscape of anticancer therapies, the search for novel agents often uncovers unexpected candidates. Among these are drugs like Ivermectin and Fenbendazole, primarily used as antiparasitics, along with naturally occurring substances such as Quercetin, Vitamins C and D3, and Curcumin. Intriguingly, these compounds have demonstrated anticancer properties in vitro and in vivo, but the path to human trials has been slow and challenging, largely due to economic considerations in the repurposing of patent-expired drugs and natural compounds.
Repurposed Drugs and Natural Compounds as Anticancer Agents
Both Ivermectin and Fenbendazole have shown anticancer potential in preclinical studies, with reported effects including cytotoxicity to cancer cells and inhibition of tumor growth. The mechanisms underlying these effects appear to involve disruption of critical cellular processes, leading to cancer cell death.
Similarly, certain flavonoids and vitamins have shown promising anticancer properties. Quercetin, a flavonoid found in many fruits and vegetables, exhibits antioxidant, anti-inflammatory, and antiproliferative activities that can potentially inhibit cancer progression. Vitamins C and D3 have also shown anticancer potential, with Vitamin C inducing oxidative stress in cancer cells, and Vitamin D3 modulating cellular growth and differentiation. Curcumin, the active component of turmeric, has also demonstrated broad anticancer effects, potentially impacting multiple signaling pathways involved in cancer.
Economic Challenges in Drug and Natural Compound Repurposing
Despite these encouraging findings, the progression towards clinical trials for these compounds as anticancer treatments has been hindered. This slow pace can be attributed largely to economic constraints. Developing or repurposing a drug is a high-cost, time-intensive process, with clinical trials alone demanding significant financial and human resources.
For Ivermectin and Fenbendazole, their status as off-patent drugs allows production by multiple manufacturers, reducing the potential for return on investment for companies funding research into their anticancer uses. For natural compounds like Quercetin, Vitamins C and D3, and Curcumin, the inability to patent these substances similarly lowers the financial incentive for pharmaceutical companies to invest in extensive research and development.
The Case for Drug and Natural Compound Repurposing
Despite these challenges, the repurposing of these compounds carries potential advantages that justify further exploration. Since the safety and pharmacokinetic profiles of these substances are well-known, their development as anticancer agents could be faster and less expensive than for new drugs. Furthermore, the successful repurposing of these compounds could provide a cost-effective way to expand anticancer treatments, possibly improving patient outcomes while reducing healthcare costs.
Conclusion
While the economic aspects of drug development are a crucial consideration, they should not impede the pursuit of potential life-saving treatments. The cases of Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin highlight the need for alternative funding models and regulatory strategies to support the repurposing of off-patent drugs and natural compounds. Potential solutions could include public-private partnerships, non-profit or government funding, modifications to patent laws, or innovative models of drug development. By exploring such alternatives, we can ensure that the potential therapeutic benefits of these compounds are fully explored and capitalized on, irrespective of their economic attractiveness to pharmaceutical companies.
References
1 Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., & Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787.
2 Pourgholami, M.H., Khachigian, L.M., Fahmy, R.G., Badar, S., Wang, L., Chu, S.W., et al. (2010). Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochemical and Biophysical Research Communications, 397(4), 729-734.
3 Granja, A., Pinheiro, M., Reis, S. (2020). Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients, 8(5), 307.
4 Padayatty, S.J., Sun, A.Y., Chen, Q., Espey, M.G., Drisko, J., & Levine, M. (2010). Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. PLoS ONE, 5(7), e11414.
5 Garland, C.F., & Garland, F.C. (1980). Do sunlight and vitamin D reduce the likelihood of colon cancer? International Journal of Epidemiology, 9(3), 227-231.
6 Hatcher, H., Planalp, R., Cho, J., Torti, F.M., & Torti, S.V. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences, 65(11), 1631-1652.
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/. Mandy Juarez,1 Alejandro Schcolnik-Cabrera,1 and Alfonso Dueñas-Gonzalez2 The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
Jun 15, 2023
I have put in an order for Petmectin for my large dog that weighs the exact same as me. Let’s see if it is delivered from the US.
Jun 15, 2023Edited
Anticancer Potential of Repurposed Drugs and Natural Compounds: A Focus on Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin
By Sid Belzberg
Introduction
In the evolving landscape of anticancer therapies, the search for novel agents often uncovers unexpected candidates. Among these are drugs like Ivermectin and Fenbendazole, primarily used as antiparasitics, along with naturally occurring substances such as Quercetin, Vitamins C and D3, and Curcumin. Intriguingly, these compounds have demonstrated anticancer properties in vitro and in vivo, but the path to human trials has been slow and challenging, largely due to economic considerations in the repurposing of patent-expired drugs and natural compounds.
Repurposed Drugs and Natural Compounds as Anticancer Agents
Both Ivermectin and Fenbendazole have shown anticancer potential in preclinical studies, with reported effects including cytotoxicity to cancer cells and inhibition of tumor growth. The mechanisms underlying these effects appear to involve disruption of critical cellular processes, leading to cancer cell death.
Similarly, certain flavonoids and vitamins have shown promising anticancer properties. Quercetin, a flavonoid found in many fruits and vegetables, exhibits antioxidant, anti-inflammatory, and antiproliferative activities that can potentially inhibit cancer progression. Vitamins C and D3 have also shown anticancer potential, with Vitamin C inducing oxidative stress in cancer cells, and Vitamin D3 modulating cellular growth and differentiation. Curcumin, the active component of turmeric, has also demonstrated broad anticancer effects, potentially impacting multiple signaling pathways involved in cancer.
Economic Challenges in Drug and Natural Compound Repurposing
Despite these encouraging findings, the progression towards clinical trials for these compounds as anticancer treatments has been hindered. This slow pace can be attributed largely to economic constraints. Developing or repurposing a drug is a high-cost, time-intensive process, with clinical trials alone demanding significant financial and human resources.
For Ivermectin and Fenbendazole, their status as off-patent drugs allows production by multiple manufacturers, reducing the potential for return on investment for companies funding research into their anticancer uses. For natural compounds like Quercetin, Vitamins C and D3, and Curcumin, the inability to patent these substances similarly lowers the financial incentive for pharmaceutical companies to invest in extensive research and development.
The Case for Drug and Natural Compound Repurposing
Despite these challenges, the repurposing of these compounds carries potential advantages that justify further exploration. Since the safety and pharmacokinetic profiles of these substances are well-known, their development as anticancer agents could be faster and less expensive than for new drugs. Furthermore, the successful repurposing of these compounds could provide a cost-effective way to expand anticancer treatments, possibly improving patient outcomes while reducing healthcare costs.
Conclusion
While the economic aspects of drug development are a crucial consideration, they should not impede the pursuit of potential life-saving treatments. The cases of Ivermectin, Fenbendazole, Quercetin, Vitamins C and D3, and Curcumin highlight the need for alternative funding models and regulatory strategies to support the repurposing of off-patent drugs and natural compounds. Potential solutions could include public-private partnerships, non-profit or government funding, modifications to patent laws, or innovative models of drug development. By exploring such alternatives, we can ensure that the potential therapeutic benefits of these compounds are fully explored and capitalized on, irrespective of their economic attractiveness to pharmaceutical companies.
References
1 Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., & Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787.
2 Pourgholami, M.H., Khachigian, L.M., Fahmy, R.G., Badar, S., Wang, L., Chu, S.W., et al. (2010). Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochemical and Biophysical Research Communications, 397(4), 729-734.
3 Granja, A., Pinheiro, M., Reis, S. (2020). Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients, 8(5), 307.
4 Padayatty, S.J., Sun, A.Y., Chen, Q., Espey, M.G., Drisko, J., & Levine, M. (2010). Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. PLoS ONE, 5(7), e11414.
5 Garland, C.F., & Garland, F.C. (1980). Do sunlight and vitamin D reduce the likelihood of colon cancer? International Journal of Epidemiology, 9(3), 227-231.
6 Hatcher, H., Planalp, R., Cho, J., Torti, F.M., & Torti, S.V. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences, 65(11), 1631-1652.
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/. Mandy Juarez,1 Alejandro Schcolnik-Cabrera,1 and Alfonso Dueñas-Gonzalez2 The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug